A new study says most fluorinated drugs have alternatives. Some of the coverage says you should ask your doctor to switch. Those are two very different claims.
A paper published in August 2026 in Sustainable Chemistry and Pharmacy, by Johanna Greinke and colleagues in Michael Müller's group at the University of Freiburg and commissioned by the German Environment Agency, asked a simple question. Of the medicines that count as PFAS ("per- and polyfluoroalkyl substances," the "forever chemicals"), how many actually need to be?
The researchers identified 111 active ingredients in human medicines, and 28 in veterinary medicines, that meet the PFAS definition. For 87% of the human ones, a non-PFAS alternative already exists for the same use, and alternatives are in development for most of the rest. For the veterinary ones the figure was 65%. They also found that most of these drugs, around 84%, can break down into trifluoroacetic acid (TFA), one of the most persistent chemicals in the environment.
That's a genuinely important finding. But some of the coverage has turned it into advice it doesn't support, so it's worth separating what the study shows from what's been layered on top.
Chemists add fluorine to drug molecules because the carbon–fluorine bond is extremely strong. It can stop a drug being broken down too quickly, help it cross into cells, or make it bind more tightly to its target. The authors' point is that fluorine is rarely what makes the drug work. It's usually tuning how long the drug lasts or where it goes, which is why alternatives exist for most of them.
That doesn't make fluorine pointless in medicine. Better stability can mean once-daily dosing instead of three times a day, and that matters for whether people actually take their tablets. "An alternative exists" isn't the same as "the alternative is equally good for you." That's a decision for each drug, made by people with the full clinical picture.
The widely shared tip is that if a drug's name contains "fluor" or "flu," it's a PFAS. That's wrong.
Under the OECD definition used in this research, a molecule only counts as PFAS if it contains at least one fully fluorinated carbon: a CF₃ or CF₂ group. Fluoxetine (Prozac) has a CF₃ group and qualifies. Ciprofloxacin has a single fluorine atom on a ring and doesn't. Plenty of fluorinated drugs aren't PFAS, and some PFAS drugs don't have "flu" anywhere in the name. You can't tell from the label, and you shouldn't try.
The strongest part of this study is about what happens after the medicine leaves your body. Drugs and their breakdown products pass through wastewater, and many end up as TFA. TFA is small and highly water-soluble. It doesn't break down in nature, and ordinary water treatment removes very little of it. Concentrations in rain, rivers and drinking water have been rising across Europe.
In June 2026, a scientific committee of the European Chemicals Agency recommended classifying TFA as a presumed reproductive toxicant, based on animal studies. It isn't law yet: the European Commission still has to adopt it, which typically takes around two years. Some campaigners have already described it as "officially classified." It isn't, and saying so doesn't help the case. The European Food Safety Authority has also proposed a safe daily intake for TFA, based on a fall in the thyroid hormone T4 in rats.
Two points of context the coverage tends to leave out:
Medicines are a small source of TFA. Germany's environment agency estimates that refrigerant and foam-blowing gases release around 2,000 tonnes of TFA a year in Germany, pesticides around 450 tonnes, and human medicines around 29. Medicines are about 1% of the problem. Designing future drugs to avoid TFA is sensible, but it won't move the needle unless refrigerants and pesticides are dealt with too. The EU stopped renewing the herbicide flufenacet in 2025, mainly because it disrupts thyroid hormones, with TFA contamination of groundwater as a further concern.
TFA isn't the same as the PFAS in the health headlines. The research linking PFAS to reduced vaccine response, raised cholesterol, thyroid effects and certain cancers is mostly about long-chain compounds like PFOA and PFOS, which stay in the human body for years. TFA is much smaller, clears from the body far faster, and doesn't build up in the same way. The environmental concern is real because it keeps accumulating in water. But borrowing health findings from PFOS and applying them to TFA, or to the fluorinated drug you take, stitches two different stories together.
Don't change or stop a medication because of this study. It wasn't about your health. It was about drug design and water. Switching a drug that's working, especially an antidepressant, steroid inhaler or antibiotic, carries real clinical risks, and those outweigh any personal PFAS benefit, which the study didn't measure. If you're starting something new and you care about the environmental side, you can ask. But it's your doctor's decision, not a lifestyle tweak.
The case for reviewing long-term medication stands on its own. Many people stay on drugs long after the original reason has gone. Asking at an annual review "is this still necessary?" is good practice whatever the drug contains.
If you want to reduce personal PFAS exposure, focus on the long-lasting kind:
This is a good study with a clear message for drug developers and regulators: think about environmental persistence at the design stage, when alternatives exist. Its real significance is regulatory. Medicines have so far been exempt from the EU's planned PFAS restriction on the grounds that they're essential. This study says most of them aren't irreplaceable, and that's the argument regulators will now have to answer, with ECHA's assessment due by the end of 2026 and a draft law expected in 2027.
It isn't evidence that your medication is harming you, and it shouldn't be dressed up as that. Pointing out that the pharmaceutical industry adds persistent chemicals for convenience is fair criticism. Telling people to question their prescriptions based on a study that didn't look at patients is overreach, and it gives the critics' own side a bad name.
Stop navigating your health by population guidelines designed for the average patient. The TDG Five-Test Programme gives you 500+ data points across hormones, gut function, organic acids, food sensitivity, and blood chemistry — and a clinical picture designed around you.
See the TDG Programme →